A phase I study of safety and immunogenicity of survivin long peptide vaccine (SurVaxM) in patients (pts) with metastatic neuroendocrine tumors (NETs).

Medhavi Gupta,Robert A. Fenstermaker,Jingxin Qiu,Renuka Iyer

A phase I study of safety and immunogenicity of survivin long peptide vaccine (SurVaxM) in patients (pts) with metastatic neuroendocrine tumors (NETs).

2021

Medhavi Gupta
Robert A. Fenstermaker
Jingxin Qiu
Renuka Iyer

TPS375Background: Metastatic neuroendocrine tumors (NETs) have a poor prognosis and there are limited options after first-line treatment with somatostatin analogues (SSA)/chemotherapy. Therefore, n...

Keywords:

Immunogenicity
Medicine
Peptide vaccine
Cancer research
in patient
Survivin
Neuroendocrine tumors
Somatostatin
Chemotherapy
phase i study

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations